Efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in a European multicenter cohort of nucleos(t)ide experienced patients with chronic hepatitis B virus (HBV)-infection

Aims: The nucleotide analogue tenofovir disoproxil fumarate (TDF) was shown to be an effective treatment for treatment-naïve patients up to three years of treatment (Marcellin & Heathcote et al, AASLD 2009). The aim of this multicenter cohort study is to study the long term outcome of TDF treatment in patients with previous failure to nucleos(t)ide analogues.